Document is current
Any future updates will be listed below
-
Authors
Hummel, Patrik https://orcid.org/0000-0001-9668-0810
Braun, Matthias
Bischoff, Serena
Samhammer, David
Seitz, Katharina
Fasching, Peter A.
Dabrock, Peter
-
Funding
Funding for this research was provided by:
Bundesministerium für Gesundheit (ZMV/1 – 2517 FSB 013)
Ministerie van Onderwijs, Cultuur en Wetenschap (NWO grant number 024.004.031)
- License Information
-
More Information
Article History
Received: 22 December 2022
Accepted: 16 November 2023
First Online: 7 January 2024
Declarations
:
: Matthias Braun declares that he received funding in the past 36 months from the German Research Foundation, the German Ministry of Health, and the German Ministry of Research and Education. Peter A. Fasching reports personal fees from Novartis, grants from Biontech, grants and personal fees from Pfizer, personal fees from Daiichi-Sankyo, personal fees from Astra Zeneca, personal fees from Eisai, personal fees from Merck Sharp & Dohme, grants from Cepheid, personal fees from Lilly, personal fees from Pierre Fabre, personal fees from SeaGen, personal fees from Roche, personal fees from Agendia, personal fees from Sanofi Aventis, and personal fees from Gilead. Patrik Hummel, Serena Bischoff, David Samhammer, Katharina Seitz and Peter Dabrock declare no conflicts of interest.
: This study received ethics approval from the Ethics Commission of the Medical Faculty of Friedrich-Alexander-Universität Erlangen-Nürnberg (project number 453_18 B).
